[ad_1] Bratislava, Nov 23 (OTS) – AXON Neuroscience (“Axon”), a biotechnology company in clinical trials and a world leader in the development of tau vaccines for the treatment and prevention of Alzheimer’s disease, announces that it has successfully tested the first therapeutic antibodies to SARS-Cov- 2. During the development of …
Read More »AXON has positive results of the potential drug ACmab1 against COVID-19
